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A note on retrograde gene transfer 
efficiency and inflammatory 
response of lentiviral vectors 
pseudotyped with FuG-E vs.  
FuG-B2 glycoproteins
Soshi tanabe1, Shiori Uezono1, Hitomi tsuge1, Maki Fujiwara1, Miki Miwa2, Shigeki Kato3, 
Katsuki Nakamura2, Kazuto Kobayashi3, Ken-ichi Inoue  1,4 & Masahiko takada1
Pseudotyped lentiviral vectors give access to pathway-selective gene manipulation via retrograde 
transfer. Two types of such lentiviral vectors have been developed. One is the so-called NeuRet vector 
pseudotyped with fusion glycoprotein type E, which preferentially transduces neurons. The other is 
the so-called HiRet vector pseudotyped with fusion glycoprotein type B2, which permits gene transfer 
into both neurons and glial cells at the injection site. Although these vectors have been applied in many 
studies investigating neural network functions, it remains unclear which vector is more appropriate 
for retrograde gene delivery in the brain. To compare the gene transfer efficiency and inflammatory 
response of the NeuRet vs. HiRet vectors, each vector was injected into the striatum in macaque 
monkeys, common marmosets, and rats. It was revealed that retrograde gene delivery of the NeuRet 
vector was equal to or greater than that of the HiRet vector. Furthermore, inflammation characterized 
by microglial and lymphocytic infiltration occurred when the HiRet vector, but not the NeuRet vector, 
was injected into the primate brain. The present results indicate that the NeuRet vector is more suitable 
than the HiRet vector for retrograde gene transfer in the primate and rodent brains.
Gene transfer of functional molecules into neurons that give rise to a particular pathway is crucial for monitoring/
manipulating neuronal activity within that pathway. Emphasis was recently placed on the development of viral 
vectors that allow us to introduce foreign genes retrogradely into a given pathway and dissect it from others. For 
example, recombinant glycoprotein-deleted rabies virus (RV) and canine adenovirus-2 (CAV-2) vectors have 
been used not only for network-tracing studies1–3 but also for network-manipulation4–6 and bioimaging studies7–9. 
However, these vectors are not suitable for chronic electrophysiological studies or gene therapeutic trials because 
of the cytotoxicity of their viral proteins. To overcome this, it is necessary to create a novel non-cytotoxic vector 
that accommodates efficient retrograde gene transfer.
Lentiviral vectors derived from human immunodeficiency virus type 1 (HIV-1) are a strong candidate since 
they exhibit low cytotoxicity because of their replication-defective form10,11. Given that these vectors are typi-
cally pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G), they are taken up preferentially from 
somas/dendrites of neurons. To enable retrograde gene transfer, pseudotyping of lentiviral vectors with rabies 
virus glycoprotein (RV-G) was attempted12,13. Later, fusion envelope glycoproteins (FuG) consisting of distinct 
combinations of RV-G and VSV-G were developed to enhance the efficiency of retrograde transgene delivery14–19. 
In particular, our research group previously reported the development of two types of lentiviral vectors with 
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highly-efficient retrograde gene transfer. One is known as HiRet vector, which is pseudotyped with the FuG-B2 
type of fusion glycoprotein formed by the extracellular and transmembrane domains of RV-G and the membrane 
proximal regions of VSV-G15,17. The other is known as NeuRet vector, which is pseudotyped with the FuG-E type 
of fusion glycoprotein consisting of the N-terminal segment of RV-G and the membrane proximal region and 
the transmembrane/cytoplasmic domains of VSV-G19. Although these lentiviral vectors permit potent tools for 
pathway-selective gene manipulation in the central nervous systems of rodents17,20–23 and primates24–26, it is still 
unclear which vector possesses a higher efficiency of retrograde transgene delivery.
There has been considerable interest in neurotoxic immune responses triggered by viral vectors transducing 
foreign proteins into antigen-presenting cells like astroglia. In fact, it has been demonstrated that transduction 
of a foreign protein (i.e., green fluorescent protein) by adeno-associated virus serotype-9 (AAV9) causes inflam-
mation associated with microglial and lymphocytic infiltration27,28. Similar to AAV9, the HiRet vector displays 
gene transfer into both neurons and glial cells at the injection site15,17. Transgene delivery into glial cells by the 
HiRet vector around the injection site might induce an adaptive immune response leading to prominent damage 
of transduced tissue. On the other hand, the NeuRet vector preferentially transduces neuronal cells and rarely 
transduces dividing glial and neural stem/progenitor cells19,29. This neuronal specificity of the NeuRet vector 
reduces the risk of tumorigenesis due to prevention of transgene insertion into the genome of dividing cells in the 
brain. However, the issue of how much of an immune response and/or neuroinflammation the HiRet and NeuRet 
vectors cause has not as yet been addressed.
The present study examined the suitability of the HiRet vs. NeuRet vectors for retrograde gene transfer in the 
brain by comparing them in terms of vector production, transgene expression, and inflammatory response. The 
striatal input system was employed as a test system, and for comparison among different species, one rodent (rats) 
and two nonhuman primate (macaques and marmosets) species were used. We have found that the NeuRet vector 
exhibits a higher retrograde gene transfer efficiency and a much weaker inflammatory response than the HiRet 
vector. This combination of properties makes the NeuRet vector more viable approach to retrograde transgene 
delivery in the brains of primates and rodents.
Results
Production efficiency of the FuG-B2 and FuG-E pseudotyped lentiviral vectors. We produced 
HIV-1-based lentiviral vectors carrying the red fluorescent protein (RFP) transgene by pseudotyping with FuG-
B2 or FuG-E glycoprotein as reported in previous studies17,19. To compare the recovery efficiency of the FuG-E 
and FuG-B2 pseudotype, the copy number of viral RNA in the vector stock solutions with the same concentration 
volume was determined by quantitative reverse transcription-PCR (Fig. 1a). The RNA copy number in the vector 
stock solution of the FuG-E pseudotype was significantly greater than that of the FuG-B2 pseudotype (Student’s 
t test, P < 0.05), and this RNA copy number of the FuG-E pseudotype was equivalent to that of the VSV-G pseu-
dotype (Supplementary Fig. S1). SDS-PAGE analysis revealed that the amount of viral protein (p24 and p17) 
content in the vector solutions adjusted to the same RNA titer (4.0 × 106 genome copies) did not differ between 
the FuG-E and FuG-B2 pseudotypes (Fig. 1b). This indicates that the vector stock solutions with identical RNA 
titer contained an equivalent number of viral vector particles. We also found that the higher-titer vector solution 
(1.6 × 107 genome copies) of the FuG-E pseudotype contained more viral protein than the lower-titer vector 
solution (Fig. 1b). These results demonstrate that the FuG-E pseudotype has a higher production efficiency than 
the FuG-B2 pseudotype. As reported in a previous study17, the FuG-B2 pseudotype transduced into HEK293T 
and Neuro2A cells, whereas the FuG-E pseudotype rarely transduced into these cells (Fig. 1c). The ratio of the 
RNA copy number to transducing units of the FuG-E pseudotype was significantly higher than that of the FuG-
B2 pseudotype in HEK293T and Neuro2A cell lines (Student’s t test, P < 0.01; Fig. 1d). These results led us to 
compare the properties of the HiRet (FuG-B2) and NeuRet (FuG-E) vectors with the same genome titer, but not 
the functional titer.
Retrograde gene transfer of the HiRet and NeuRet vectors in macaque monkeys. To compare 
the efficiency of retrograde gene delivery of the HiRet (FuG-B2) and NeuRet (FuG-E) vectors in the brain of 
macaque monkeys, striatal injections of each vector encoding the RFP gene were made stereotaxically into both 
the caudate nucleus and the putamen (Fig. 2a). We first injected the HiRet vector (2.5 × 1010 genome copies/ml, 
60 µl) and the NeuRet vector with an equivalent titer (2.5 × 1010 genome copies/ml, 60 µl). Since the production 
efficacy of the NeuRet vector is higher than that of the HiRet vector, we then injected the NeuRet vector with 
a higher titer (7.5 × 1010 genome copies/ml, 60 µl). To investigate the properties of gene transduction around 
the injection sites using both vectors with the same titer (2.5 × 1010 genome copies/ml), double immunofluo-
rescence histochemistry was performed for RFP and either of the neuronal marker, neuronal nuclei (NeuN), 
or the astroglial marker, glial fibrillary acidic protein (GFAP) (Fig. 2b). The ratio of RFP + NeuN-positive or 
RFP + GFAP-positive cells to the total RFP-positive cells was analyzed. In the NeuRet vector injection case, 
almost all RFP-positive cells co-expressed NeuN (n = 2; 94.1% and 94.3%), while only a few RFP-positive cells 
co-expressed GFAP (n = 2; 3.2% and 3.5%), as we reported previously29. In the HiRet vector injection case, on 
the other hand, a large number of RFP-positive cells also co-expressed GFAP (n = 2; 32.1% and 28.2%), as well as 
for NeuN (n = 2; 76.3% and 51.5%). Thus, the HiRet vector exhibited gene transfer into both neurons and glial 
cells at the injection site, as reported in mice15,17, whereas the NeuRet vector showed marked neuronal specificity.
To compare the efficacy of retrograde gene delivery of the HiRet and NeuRet vectors with the same titer 
(2.5 × 1010 genome copies/ml), we analyzed the density of neuronal labeling in the substantia nigra pars compacta 
(SNc), the centromedian-parafascicular thalamic complex (CM-Pf), and the supplementary motor area (SMA). 
In the SNc and CM-Pf, somewhat larger numbers of RFP-positive neurons were found after the injection of the 
NeuRet than the HiRet vector (Fig. 3a). The average number of RFP-positive neurons transduced with the HiRet 
or NeuRet vector in the SNc was 456.2 or 520.6 cells per section (n = 2), respectively (Fig. 3b; NeuRet/HiRet 
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ratio = 1.1), while that of RFP-positive CM-Pf neurons in the HiRet or NeuRet vector injection case was 408.7 
or 500.0, respectively (Fig. 3c; NeuRet/HiRet ratio = 1.2). Double immunofluorescence histochemistry for RFP 
and the dopaminergic neuron marker, tyrosine hydroxylase (TH), confirmed that substantially all RFP-positive 
neurons in the SNc were also immunostained for TH, and nearly half of the total TH-immunostained neurons 
expressed the RFP transgene in the NeuRet (46.3%; n = 2) and HiRet (43.5%; n = 2) vector injection cases. On 
the other hand, the HiRet and NeuRet vectors with the same titer (2.5 × 1010 genome copies/ml) transduced only 
a small number of neurons in the SMA, though neuronal labeling with the NeuRet vector was still noticeable in 
the ipsilateral hemisphere (Fig. 3a). However, a large number of labeled neurons were observed not only in the 
ipsilateral but also in the contralateral SMA after the injection of the NeuRet vector with a higher titer (7.5 × 1010 
genome copies/ml). The density of RFP-positive neurons in the case of injecting the higher-titer NeuRet vector 
was greater than that in the case of the lower-titer NeuRet vector by approximately 1.9 or 4.0 times in the ipsilat-
eral or contralateral SMA, respectively (Fig. 3c).
Retrograde gene transfer of the HiRet and NeuRet vectors in marmosets. To compare retrograde gene 
transfer of the HiRet and NeuRet vectors in the brain of common marmosets, we injected each vector with the same 
titer (1.0 × 1010 genome copies/ml, 10 µl) into the striatum (Fig. 4a). For analyzing the extent of glial transduction at the 
injection site of each vector, double immunofluorescence histochemistry for RFP and GFAP was performed. Consistent 
with the results obtained in the macaque monkeys, many RFP-positive cells co-expressed GFAP in the HiRet vector 
injection case, while few RFP-positive cells co-expressed GFAP in the NeuRet vector injection case. We analyzed the 
density of labeled neurons in the SNc, CM-Pf, and Brodmann’s area 6 m (A6m). In the SNc, many RFP-positive neurons 
were observed after the NeuRet than the HiRet vector injection (Fig. 4b). The mean number of RFP-positive neurons in 
the HiRet or NeuRet vector injection case was 86.0 or 120.0 cells per section (n = 2), respectively (Fig. 4c; NeuRet/HiRet 
ratio = 1.4). Similar, but clearer, data about the superiority of the NeuRet vector were obtained for neuronal labeling 
in the CM-Pf (Fig. 4b) and A6m (Fig. 4b). The mean number of RFP-positive CM-Pf neurons in the HiRet or NeuRet 
vector injection case was 215.5 or 501.1 cells per section (n = 2), respectively (Fig. 4c; NeuRet/HiRet ratio = 2.3). The 
density of RFP-positive A6m neurons in the HiRet or NeuRet vector injection case was 34.6 or 70.1 for the ipsilateral 
hemisphere (n = 2), respectively (Fig. 4d; NeuRet/HiRet ratio = 2.0), and it was 18.1 or 36.3 for the contralateral hemi-
sphere (n = 2), respectively (Fig. 4d; NeuRet/HiRet ratio = 2.0).
Retrograde gene transfer of the HiRet and NeuRet vectors in rats. To compare the extent of ret-
rograde gene transfer of the HiRet and NeuRet vectors in the rat brain, we injected each vector with the same 
titer (1.0 × 1010 genome copies/ml, 2 µl) into the striatum (Fig. 5a). We analyzed the number and density of 
neuronal labeling in the SNc, Pf, and the primary motor cortex (M1). In the SNc, the equivalent number of 
RFP-positive neurons was observed after the injections of the HiRet and NeuRet vectors (Fig. 5b). The mean 
number of RFP-positive neurons in the SNc was 95.0 ± 2.7 or 89.3 ± 4.8 cells per section (n = 4) in the HiRet or 
NeuRet vector injection case (Student’s t test, P = 0.341; Fig. 5c; NeuRet/HiRet ratio = 0.9). On the other hand, 
Figure 1. Production efficiency of pseudotyped lentiviral vectors. HEK293T cells in 72 10-cm tissue culture 
dishes were transfected with the envelope plasmid encoding FuG-E or FuG-B2, together with the transfer plasmid 
encoding RFP and packaging plasmids. Vector particles were concentrated by centrifugation, purified with 
ion-exchange chromatography and finally prepared in 110 μl of PBS. (a) The yield in the vector stock solutions 
measured by quantitative reverse transcription-PCR analysis (open bar for FuG-B2, gray bar for FuG-E). Each 
value was obtained from five individual experiments and expressed as the mean ± SEM. *P < 0.05, significant 
difference from the FuG-B2 pseudotype (Student’s t test). (b) Fluorescent images of SDS-PAGE of the viral protein 
(p24 and p17) from vectors pseudotyped with FuG-B2 (4.0 × 106 genome copies) and FuG-E (4.0 × 106 and 
1.6 × 107 genome copies). A full-length gel image is presented in Supplementary Fig. S3. (c) Fluorescent images of 
Hoechst-stained HEK293T and Neuro2A (NA) cells after transduction of the vectors pseudotyped with FuG-B2 
and FuG-E (100 genome copies/cell). Scale bar, 50 μm. (d) Ratio of the RNA genome copies to the transduction 
units (open bars for FuG-B2, gray bars for FuG-E). Each value was obtained from five individual experiments and 
expressed as the mean ± SEM. **P < 0.01, significant difference from the FuG-B2 vector (Student’s t test).
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the significant superiority of the NeuRet vector was obtained for neuronal labeling in the Pf and M1 (Fig. 5b). 
The average numbers of RFP-positive neurons in the Pf were 246.1 ± 11.1 or 399.5 ± 24.3 cells per section (n = 4) 
in the HiRet or NeuRet vector injection case (Student’s t test, P < 0.01; Fig. 5c; NeuRet/HiRet ratio = 1.6). The 
density of RFP-positive M1 neurons in the HiRet or NeuRet vector injection case was 84.0 ± 3.7 or 198.7 ± 16.1 
for the ipsilateral hemisphere (n = 4), respectively (Student’s t test, P < 0.01; Fig. 5d; NeuRet/HiRet ratio = 2.4), 
and it was 6.1 ± 0.6 or 68.2 ± 1.8 for the contralateral hemisphere (n = 4), respectively (Student’s t test, P < 0.001; 
Fig. 5d; NeuRet/HiRet ratio = 11.2).
Neuroinflammatory responses of the HiRet and NeuRet vectors. As previously reported in mice17,19, 
we have shown that the HiRet vector transduces not only neurons but also glial cells, while the NeuRet vector pre-
dominantly transduces neurons in primates. The HiRet vector may thus trigger an immune response due to the 
introduction of non-self proteins into antigen-presenting cells around the injection site. In Nissl-stained sections 
from macaque monkeys injected with the HiRet vector, severe necrosis occurred around the injection site (Fig. 6a). 
To clarify whether this tissue damage related to the immune response, immunofluorescence histochemistry for the 
microglial marker, ionized calcium-binding adapter molecule 1 (Iba1), and the cytotoxic T cell marker, cluster of 
differentiation 8 (CD8) was performed. Many Iba1- and CD8-positive cells were observed around the injection site 
in the HiRet vector injection case, indicating that microglial and lymphocytic infiltration appeared. In contrast to the 
HiRet vector, no marked necrosis around the injection site was observed after the injections of lower or higher titer 
of the NeuRet vector. In the marmoset striatum, similar necrotic and microglial/lymphocytic infiltrative events were 
seen in the HiRet vector, but not the NeuRet vector injection case (Supplementary Fig. S2). Following the intrastri-
atal injections of either vector, no tissue damage was detected in the rat brain (Fig. 6b).
Discussion
In previous studies15–17,19, it has been reported that pseudotyping a lentiviral vector with modified envelope glyco-
proteins, formed by RV-G and VSV-G, can improve the efficiency of gene transfer through retrograde transport of 
the vector. This capability of the pseudotyped lentiviral vectors enables us to express a foreign gene in a particular 
circuit and remove/manipulate the circuit, not only in rodents17,20–23 but also in nonhuman primates24–26. In our 
present work, we investigated the efficacy of transgene expression by the HiRet (FuG-B2) and NeuRet (FuG-E) 
vectors through the intrastriatal injection of each vector in macaque monkeys, marmosets, and rats. First, we 
showed that the efficiency of retrograde gene delivery of the NeuRet vector is greater than or equal to that of the 
HiRet vector, though this depended on the pathway or the species examined. It should be noted, however, that 
Figure 2. Pattern of gene transfer of the HiRet and NeuRet vectors around injection sites in macaque monkeys. 
The HiRet and NeuRet lentiviral vectors (each 2.5 × 1010 genome copies/ml) were injected into the putamen 
(Put) of macaque monkeys, and histological analyses were performed in the brains fixed at four weeks 
postinjection. (a) Nissl staining and RFP immunostaining at the injection sites of the HiRet (left) and NeuRet 
(right) vectors with the same titer. ac, anterior commissure; Cd, caudate nucleus; GPe, external segment of the 
globus pallidus; GPi, internal segment of the globus pallidus; ic, internal capsule. Scale bar, 2 mm. (b) Double 
immunostaining for RFP (red) and NeuN (upper; green) or GFAP (lower; green) at injection sites of the HiRet 
(left) and NeuRet (right) vectors. Shown in yellow are double-immunostained cells. Scale bars, 50 μm.
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injections of the HiRet vector and the low-titer NeuRet vector into the macaque striatum did not sufficiently 
label SMA neurons through the corticostriatal pathway. As also reported elsewhere29, the NeuRet vector with a 
higher titer resulted in highly efficient retrograde gene transduction in the corticostriatal pathway, as well as in 
the nigrostriatal and thalamostriatal pathways. Second, our data also showed that the NeuRet vector exhibits a 
smaller degree of tissue inflammation than the HiRet vector. Thus, the NeuRet vector could provide a powerful 
and safe tool to investigate the functional roles of a given pathway in both primates and rodents.
Figure 3. Transgene expression after intrastriatal injections of the HiRet and NeuRet vectors in macaque 
monkeys. Intrastriatal injections of HiRet (2.5 × 1010 genome copies/ml) and NeuRet (2.5 × 1010 and 7.5 × 1010 
genome copies/ml) pseudotyped lentiviral vectors were made in macaque monkeys, and histological analyses 
were performed in the brains fixed at four weeks postinjection. (a) RFP immunostaining in the substantia nigra 
pars compacta (SNc), centromedian nucleus (CM), and supplementary motor area (SMA) of the ipsilateral and 
contralateral hemispheres for the HiRet (top), lower-titer NeuRet (middle), and higher-titer NeuRet (bottom) 
vectors. cp, cerebral peduncle; MD, mediodorsal nucleus; SNr, substantia nigra pars reticulate; III, layer III; V, 
layer V. Scale bars, 1 mm for SNc and CM, 500 μm for SMA. (b) Number of RFP-positive neurons in the SNc and 
the centromedian-parafascicular complex (CM-Pf). Eleven or seven sections were used for cell counts in the 
SNc or CM-Pf, respectively. (c) Density of RFP-positive neurons in the SMA of the ipsilateral and contralateral 
hemispheres. Ten sections were analyzed. Each symbol (open or filled circle, triangle, or square) indicates data 
for each animal, and the same symbol represents data for the same animal. Averaged data (n = 2) are denoted by 
open (for the HiRet vector), filled (for the NeuRet vector with lower titer), and gray (for the NeuRet vector with 
higher titer) bars.
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Figure 4. Transgene expression after intrastriatal injections of the HiRet and NeuRet vectors in marmosets. The 
HiRet and NeuRet vectors (each 1.0 × 1010 genome copies/ml) were injected into the Cd and Put of marmosets, and 
histological analyses were performed in the brains fixed at four weeks postinjection. (a) Injection sites of the HiRet 
(upper; gray) and NeuRet (lower; gray) vectors and cells double-immunostained for RFP (red) and GFAP (green) at 
the injection sites. Shown in yellow are double-immunostained cells. Scale bars, 1 mm for injection sites, 50 μm for 
double-immunostained cells. (b) RFP immunostaining in the SNc, CM-Pf, and Brodmann’s area 6 m (A6m) of the 
ipsilateral and contralateral hemispheres for the HiRet (upper) and NeuRet (lower) vectors. The roman numerals in 
each A6m panel indicate the cortical layers. fr, fasciculus retroflexus; Pf, parafascicular nucleus. Scale bars, 500 μm. 
(c) Number of RFP-positive neurons in the SNc and CM-Pf. Seven or four sections were used for cell counts in the 
SNc or CM-Pf, respectively. (d) Density of RFP-positive neurons in the A6m of the ipsilateral and contralateral 
hemispheres. Eight sections were analyzed. Each symbol (open or filled circle or triangle) indicates data for each 
animal, and the same symbol represents data for the same animal. Averaged data (n = 2) are denoted by open (for 
the HiRet vector) and filled (for the NeuRet vector) bars. Other conventions are as in Figs 2 and 3.
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The pathway/species-dependent differences observed in gene transfer efficacy highlights a critical issue in 
pathway-selective gene manipulation. We have shown that injections of the NeuRet vector achieve efficient ret-
rograde gene transduction into nigrostriatal, thalamostriatal, and corticostriatal neurons not only in macaque 
monkeys (see also Tanabe et al., 2017) but also in marmosets and rats. This indicates that regardless of the stri-
atal input system, the NeuRet vector successfully transduces foreign genes in multiple species. Of particular 
interest is that the pseudotyped lentiviral vectors only poorly induced retrograde gene transfer into nigrostriatal 
Figure 5. Transgene expression after intrastriatal injections of the HiRet and NeuRet vectors in rats. The 
HiRet and NeuRet vectors (each 1.0 × 1010 genome copies/ml) were injected into the striatum (Str) of rats, 
and histological analyses were performed in the brains fixed at four weeks postinjection. (a) Nissl staining and 
RFP immunostaining at the injection sites of the HiRet (left) and NeuRet (right) vectors. LV, lateral ventricle. 
Scale bar, 1 mm. (b) RFP immunostaining in the SNc, Pf, and primary motor cortex (M1) of the ipsilateral and 
contralateral hemispheres for the HiRet (upper) and NeuRet (lower) vectors. In each M1 panel, a Nissl-stained 
image of the corresponding region is also depicted. Scale bars, 500 μm for SNc, Pf, and M1. (c) Number of RFP-
positive neurons in the SNc and Pf. Six or four sections were used for cell counts in the SNc or Pf, respectively. 
(d) Density of RFP-positive neurons in the M1 of the ipsilateral and contralateral hemispheres. Four sections 
were analyzed. Averaged data (n = 4 for each group; error bar, SEM) are denoted by open (for the HiRet vector) 
and filled (for the NeuRet vector) bars. **P < 0.01, ***P < 0.001, significant difference from the HiRet vector 
(Student’s t test). Other conventions are as in Figs 2–4.
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dopaminergic neurons in mice15,16. It is therefore important to clarify the mechanisms underlying the pathway/
species-dependence in retrograde gene transduction efficiency.
Figure 6. Inflammatory responses after intrastriatal injections of the HiRet and NeuRet vectors in macaque 
monkeys and rats. (a) Nissl staining, RFP-native fluorescence (red), and immunofluorescent staining for Iba1 
(green) and CD8 (magenta) at the injection sites of the HiRet (top), lower-titer NeuRet (middle), and higher-
titer NeuRet (bottom) vectors in macaque monkeys. Put, putamen, Scale bar, 500 μm. (b) Nissl staining, RFP-
native fluorescence (red), and immunofluorescent staining for Iba1 (green) and CD8 (magenta) at the injection 
sites of the HiRet (upper) and NeuRet (lower) vectors in rats. Str, striatum. Scale bar, 500 μm.
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Concerning tissue inflammation, there was a significant difference between the NeuRet and HiRet vectors. The 
former preferentially transduces neuronal cells, whereas the latter induces gene delivery into glial cells around 
the injection site. This is crucial because a neurotoxic immune response may be caused by transducing foreign 
proteins into antigen-presenting cells. Recently, it has been demonstrated that the capability of AAV9 to trans-
duce antigen-presenting cells in the central nervous systems of rodents and primates provokes the cell-mediated 
immune response and neuroinflammation27,28. In the present study, we observed immune/neuroinflammatory 
responses around the injection site when the HiRet vector was injected into primate brains. On the other hand, 
there was no such event in the case of the NeuRet vector injection. It is of interest that in the rat brain, necrosis 
was not seen around the injection site not only with the NeuRet vector but also with the HiRet vector, as previ-
ously reported in mice17,23. These results emphasize the safety of the NeuRet vector, and inversely raise an alert 
over the use of the HiRet vector especially in the primate brain.
In addition to the pseudotyped lentiviral vectors, there are some other viral vectors that permit retrograde 
gene transfer in the central nervous system. Recombinant glycoprotein-deleted RV and CAV-2 vectors have 
so far been utilized as tools for manipulating neuronal activity, for example in optogenetics4,5. However, the 
potential cytotoxicity of these vectors may constrain long-term experiments or clinical applications. It is there-
fore necessary to develop a novel non-cytotoxic vector. In this regard, RV vectors with low cytotoxicity, such 
as self-inactivated RV vector30 and double-deletion-mutant RV vector31, have recently been introduced. These 
RV vectors have been shown to express transgene only transiently and insufficiently, so they rely on Cre- or 
Flp-mediated recombination and require other helper viral vectors or reporter conditional mouse lines. In addi-
tion, a new variant of adeno-associated viral vector termed rAAV2-retro has been developed to induce transgene 
expression robustly in a retrograde fashion32. However, this vector has been reported to have stronger tropisms 
for particular cell types in mice than the double-deletion-mutant RV vector31. Moreover, a major disadvantage of 
the AAV vector is the limited packaging size of transgene (<5 kb)33, compared with the packaging size of lentiviral 
vectors (<7.5 kb)34. To identify the most appropriate vector for retrograde gene transfer, further investigations are 
needed to compare the NeuRet vector with the above vectors from various perspectives, such as their efficiency, 
cytotoxicity, and the pathways involved.
The HIV-1-based lentiviral vector has been utilized for pathway-selective gene manipulation17,20–26 and gene 
therapeutic approaches to Parkinson’s disease in rodents and nonhuman primates35–38. Our study demonstrates 
that the NeuRet vector achieves a higher efficiency of gene delivery than the HiRet vector in the primate and 
rodent brains. Moreover, the NeuRet vector induces immune/inflammatory responses to a lesser extent than does 
the HiRet vector. This property of the NeuRet vector is ascribable to its high neuronal specificity, which mini-
mizes adverse side-effects such as neuronal loss adjacent to the injection site. In conclusion, the NeuRet vector 
pseudotyped with FuG-E might gain easy access to successful pathway-specific gene manipulations or effective 
gene therapeutic trials against neurological disorders such as Parkinson’s disease through improved and safe 
retrograde delivery.
Methods
Animals. Ten adult nonhuman primates of either sex and eight adult male Wistar rats (250–350 g) were used 
for this study. Of the 10 nonhuman primates, six animals were macaque monkeys (four Japanese monkeys, 5.6–
6.2 kg; two rhesus monkeys, 5.6–6.2 kg), and four animals were common marmosets (260–360 g). The experimen-
tal procedures were in accordance with protocols approved by the Animal Welfare and Animal Care Committee 
of the Primate Research Institute, Kyoto University (Permission Number: 2015-033), and were conducted in line 
with the Guidelines for Care and Use of Nonhuman Primates established by the Primate Research Institute, Kyoto 
University (2010). Since the Guidelines require us to consider 3R-type recommendations in designing monkey 
experiments, we decided to use two animals for each purpose. All experiments were performed in a special labo-
ratory (biosafety level 2) designated for in vivo animal infectious experiments that had been placed at the Primate 
Research Institute, Kyoto University. Throughout the entire experiments, the animals were kept in individual 
cages that were placed inside a special safety cabinet. The room temperature (23–26 °C for macaque monkeys 
and rats; 26–30 °C for marmosets) and the light condition (12-hr on/off cycle) were controlled. The animals were 
fed usually with dietary pellets and had free access to water. Every effort was made to minimize animal suffering.
Viral vector production. The construction of envelope plasmids (pCAGGS-FuG-B2 and pCAGGS-FuG-E) 
was mentioned elsewhere17,19. The transfer plasmid (pCL20c-MSCV-cgfTagRFP) contained the cDNA encoding 
cysteine- and glycan-free (cgf) TagRFP39 under the control of the murine stem-cell virus (MSCV) promoter. DNA 
transfection and viral vector preparation were carried out as previously described19,29. Briefly, HEK293T cells in 
72 10-cm tissue culture dishes were transfected with transfer, envelope, and packaging plasmids (pCAG-kGP4.1R 
and pCAG4-RTR2) by using the calcium-phosphate precipitation method. Eighteen hours after transfection, the 
medium was exchanged to a fresh one, where the cells were incubated for 24 hr. The medium was then harvested 
and filtered through a 0.45-µm Millex-HV filter unit (Millipore, USA). Viral vector particles were collected by 
centrifugation at 6,000 × g for 16–18 hr and resuspended in 0.01 M phosphate-buffered saline (PBS). The particles 
were applied to a Sepharose Q FF ion-exchange column (GE Healthcare, UK) in 0.01 M PBS and eluted with a 
linear <1.5 M NaCl gradient. The fractions were monitored at 260/280 nm of absorbance wavelength. The peak 
fractions containing the particles were collected and condensed to 110 µl by centrifugation through a Vivaspin 
filter (Vivascience, UK).
To measure RNA titer, viral RNA in 50 nl of the vector stock solution was isolated by using a NucleoSpin RNA 
virus kit (Takara, Japan), and the copy number of the RNA genome was determined by quantitative PCR with 
Taq-Man technology (Thermo Fisher Scientific, USA). The viral protein signals of the HiRet vector (4.0 × 106 
genome copies) and the NeuRet vector (4.0 × 106 and 1.6 × 107 genome copies) were visualized by 4–12% 
SDS-acrylamide gel electrophoresis and fluorescent staining (Oriole, BIO-RAD, USA). HEK293T and Neuro2A 
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cells were transduced with the viral vectors (100 genome copies/cell), and stained with Hoechst 33342 (Thermo 
Fisher Scientific, USA). The transducing unit was estimated by flow cytometry (FACSCanto II, BD Biosciences, 
USA). The RNA copy number of each vector was divided by the transduction unit to calculate the ratio of the 
RNA copy number to transducing units in each five individual experiment.
Surgical procedures. The macaque monkeys were initially sedated with ketamine hydrochloride (5 mg/kg, 
i.m.) and xylazine hydrochloride (0.5 mg/kg, i.m.), and then anesthetized with sodium pentobarbital (20 mg/kg, 
i.v.). During the surgery, the monkeys were kept hydrated with a lactated Ringer’s solution (i.v.). An antibiotic 
(Ceftazidime; 25 mg/kg, i.v.) and an analgesic (Meloxicam; 0.2 mg/kg, s.c.) were applied at the initial anesthesia. 
After removal of a portion of the skull, multiple injections of each vector were made unilaterally into the stria-
tum by means of a magnetic resonance imaging (MRI)-guided navigation system (Brainsight Primate, Rogue 
Research, Canada). In total, 60 µl of the FuG-B2 (2.5 × 1010 genome copies/ml) or FuG-E (2.5 × 1010 or 7.5 × 1010 
genome copies/ml) pseudotyped lentiviral vector was injected through a 10-µl Hamilton microsyringe into both 
the caudate nucleus and the putamen at six rostrocaudal levels (3–5 µl/site, two sites per track, eight tracks per 
monkey; three tracks for the caudate nucleus and five tracks for the putamen). After the injections, the scalp inci-
sion was sutured. The monkeys were monitored until the full recovery from the anesthesia.
The marmosets were initially sedated with ketamine hydrochloride (50 mg/kg, i.m.) and xylazine hydro-
chloride (2 mg/kg, i.m.), and then anesthetized with sodium pentobarbital (15 mg/kg, i.p.). An antibiotic 
(Cefmetazole; 25 mg/kg, i.m.) and 10 ml of acetated Ringer’s solution (s.c.) were administrated before and after 
the operation. After the craniotomy, multiple injections of each vector were made unilaterally into the striatum 
of which coordinates were measured by using MRI. In total, 10 µl of the FuG-B2 or FuG-E pseudotyped lentiviral 
vector (each 1.0 × 1010 genome copies/ml) was injected through a 10-µl Hamilton microsyringe into both the cau-
date nucleus and the putamen at three rostrocaudal levels (1 µl/site, two sites per track, five tracks per marmoset; 
three tracks for the caudate nucleus and two tracks for the putamen). After the injections, the scalp incision was 
sutured, and an analgesic (Meloxicam; 1 mg/kg, s.c.) was applied.
The rats were anesthetized with a combination of ketamine hydrochloride (50 mg/kg, i.m.) and xylazine 
hydrochloride (4 mg/kg, i.m.). In total, 2 µl of the FuG-B2 or FuG-E pseudotyped lentiviral vector (each 1.0 × 1010 
genome copies/ml) was stereotaxically injected into the right dorsal striatum (0.5 µl/site, four sites) through a 
glass microinjection capillary connected to a microinfusion pump. The anteroposterior, mediolateral, and dors-
oventral coordinates (mm) from the bregma and dura were 1.5/2.8/5.8, 1.5/2.8/4.0, 0.0/3.5/5.5 and 0.0/3.5/4.0 for 
the dorsal striatum according to an atlas of the rat brain40.
Immunohistochemistry. After a survival period of four weeks, the animals were deeply anesthetized with 
an overdose of sodium pentobarbital (50 mg/kg, i.v., for macaque monkeys; 50 mg/kg, i.p., for marmosets; 100 mg/
kg, i.p., for rats) and perfused transcardially with 0.1 M PBS, followed by 10% formalin in 0.1 M phosphate buffer. 
The removed brains were postfixed in the same fresh fixative overnight at 4 °C, and saturated with 30% sucrose 
in 0.1 M PBS at 4 °C. A freezing microtome was used to cut coronal sections serially at the 50-µm thickness for 
macaque monkeys and the 40-µm thickness for marmosets and rats. Every tenth section was mounted onto 
gelatin-coated glass slides and Nissl-stained with 1% Cresyl violet.
Immunoperoxidase staining for tRFP was performed as described previously29. The sections were pretreated 
with 0.3% H2O2 for 30 min, rinsed three times in 0.1 M PBS, and immersed in 1% skim milk for 1 hr. Then, the 
sections were incubated for 2 days at 4 °C with rabbit polyclonal anti-tRFP antibody (1:2,500 dilution; Thermo 
Fisher Scientific) in 0.1 M PBS containing 2% normal donkey serum and 0.1% Triton X-100. The sections were 
subsequently incubated with biotinylated donkey anti-rabbit IgG antibody (1:1,000 dilution; Jackson laboratories, 
USA) in the same fresh medium for 2 hr at room temperature, followed by the avidin-biotin-peroxidase complex 
kit (ABC Elite; 1:200 dilution; Vector laboratories, USA) in 0.1 M PBS for 2 hr at room temperature. The sections 
were reacted for 10–20 min in 0.05 M Tris-HCl buffer (pH 7.6) containing 0.04% diaminobenzine tetrahydro-
chloride (Wako, Japan), 0.04% NiCl2, and 0.002% H2O2. The reaction time was set to make the density of back-
ground immunostaining almost identical. These sections were counterstained with 0.5% Neutral red, mounted 
onto gelatin-coated glass slides, dehydrated, and coverslipped.
For double immunofluorescence histochemistry for RFP and one of NeuN, GFAP, and TH, the sections were 
immersed in 1% skim milk for 1 hr and incubated for 2 days at 4 °C with rabbit polyclonal anti-tRFP antibody 
(1:1,000 dilution; Thermo Fisher Scientific) and mouse monoclonal antibodies; anti-NeuN antibody (1:2000 
dilution; Millipore, USA), anti-GFAP antibody (1:500 dilution; Sigma, USA), and anti-TH antibody (1:500 
dilution; Millipore). The sections were subsequently incubated for 2 hr at room temperature with a cocktail of 
Cy3-conjugated donkey anti-rabbit IgG antibody (1:400 dilution; Jackson laboratories) and Alexa 647-conjugated 
donkey anti-mouse IgG antibody (1:400 dilution; Jackson laboratories) in the same fresh medium. For double 
immunofluorescence histochemistry for Iba1 and CD8, rabbit monoclonal anti-Iba1 antibody (1:1,000 dilution; 
Wako), mouse monoclonal anti-CD8 antibody (1:1,000 dilution; Bio-Rad, USA), Alexa 488-conjugated donkey 
anti-rabbit IgG antibody (1:200 dilution; Jackson laboratories), and Alexa 647-conjugated donkey anti-mouse 
IgG antibody (1:200 dilution; Jackson laboratories) were used following the staining protocol described above.
Image acquisition and histological analyses. To capture brightfield microscopic images, an optical 
microscope equipped with a high-grade charge-coupled device (CCD) camera (Biorevo, Keyence, Japan) and 
a scientific CMOS camera (In Cell Analyzer 2200, GE Healthcare) were used. A confocal laser-scanning micro-
scope (LSM800, Carl Zeiss, USA) were used to take fluorescent microscopic images. The number or density of 
RFP-positive cells in each brain region were calculated with Neurolucida software (MicroBrightField, USA) and 
Matlab software (Mathworks, USA), as previously described29. For counts of RFP-positive cells in the SNc, 11, 7, 
or 6 sections were used in macaque monkeys (500-μm apart), marmosets (400-μm apart) or rats (320-μm apart), 
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respectively. For counts of RFP-positive cells in the CM-Pf or Pf thalamic nucleus, 7, 4, or 4 sections were used in 
macaque monkeys, marmosets or rats, respectively. For measurements of the density of RFP-positive cells in the 
cortical areas, 10, 8, or 4 sections were used for the macaque SMA in macaque monkeys, area A6m in marmosets, 
or M1 in rats, respectively. Stereological cell counting assisted with StereoInvestigator software (MBF Biosciences, 
USA) was performed to estimate the ratio of RFP + NeuN-positive or RFP + GFAP-positive cells to the total 
RFP-positive cells at the injection sites and the ratio of RFP-positive cells to the total TH-positive cells in the SNc. 
Labeled cells in 100-μm × 100-μm counting frames equally spaced across a 500-μm × 500-μm grid were counted 
with an 18-μm-high optical dissector.
Statistics. Values were expressed as the mean ± SEM of the data. For statistical comparisons, Student’s t tests 
were used with significance set at *P < 0.05, **P < 0.01, or ***P < 0.001.
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